CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning

3.3. Top winning strategies
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Upsurge in NASH-affected population
3.4.1.2. Rise in prevalence of diabetes & obesity
3.4.1.3. Surge in healthcare expenditures worldwide

3.4.2. Restraints

3.4.2.1. Insufficient diagnostic technologies for NASH
3.4.2.2. Poor demand in the underdeveloped countries

3.4.3. Opportunities

3.4.3.1. Strong presence of pipeline drugs
3.4.3.2. Unmet needs for NASH therapeutics
3.4.3.3. Growth opportunities in the emerging markets

3.4.4. Impact analyses

3.5. Pipeline analyses

CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Vitamin E & pioglitazone

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region

4.3. Obeticholic acid

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region

4.4. Elafibranor

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region

4.5. Selonsertib & cenicriviroc

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region

CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospital pharmacy

5.2.1. Market size and forecast, by region

5.3. Online providers

5.3.1. Market size and forecast, by region

5.4. Retail pharmacy

5.4.1. Market size and forecast, by region

CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S. market size and forecast
6.2.2.2. Canada market size and forecast
6.2.2.3. Mexico market size and forecast

6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany market size and forecast
6.3.2.2. France market size and forecast
6.3.2.3. UK market size and forecast
6.3.2.4. Italy market size and forecast
6.3.2.5. Spain market size and forecast
6.3.2.6. Rest of Europe market size and forecast

6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan market size and forecast
6.4.2.2. China market size and forecast
6.4.2.3. Australia market size and forecast
6.4.2.4. India market size and forecast
6.4.2.5. South Korea market size and forecast
6.4.2.6. Rest of Asia-Pacific market size and forecast

6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil market size and forecast
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.3. South Africa market size and forecast
6.5.2.4. Rest of LAMEA market size and forecast

6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel

CHAPTER 7: COMPANY PROFILES

7.1. Allergan Plc (Tobira Therapeutics Inc.)

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. Cadila Healthcare Ltd.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance

7.3. Conatus Pharmaceuticals, Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Galmed Pharmaceuticals Ltd.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Gemphire Therapeutics Inc.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments

7.6. Genfit SA

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Gilead Sciences, Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Intercept Pharmaceuticals, Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Novartis International AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Shire plc

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments